

CLINICAL CANCER RESEARCH

# TABLE OF CONTENTS

## HIGHLIGHTS

369 Selected Articles from This Issue

## SPECIAL FEATURES

### CCR Translations

- 371** **Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?**  
Amy S. Clark, Igor Makhlin, and Angela DeMichele  
See related articles, p. 408 and p. 418
- 374** **Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy**  
Diego Salas-Benito, Iñaki Eguren-Santamaria, and Miguel F. Sanmamed  
See related article, p. 492
- 377** **A New Generation of “Magic Bullets” for Molecular Targeting of Cancer**  
Jacek Capala and Charles A. Kunos  
See related article, p. 532
- 380** **CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer**  
Tamara L. Lotan and Emmanuel S. Antonarakis  
See related article, p. 566

### Reviews

- 383** **Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies**  
Matthew S. Waitkus and Hai Yan
- 389** **Sebaceous Carcinoma Epidemiology and Genetics: Emerging Concepts and Clinical Implications for Screening, Prevention, and Treatment**  
Michael R. Sargen, Gabriel J. Starrett, Eric A. Engels, Elizabeth K. Cahoon, Margaret A. Tucker, and Alisa M. Goldstein

**394** **Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop**

**A C** Kristen L. Mueller, Marc R. Theoret, Steven J. Lemery, Laleh Amiri-Kordestani, Charlotte E. Ariyan, Michael B. Atkins, Donald A. Berry, Christian U. Blank, Angela M. DeMichele, Patrick M. Forde, Nageatte Ibrahim, Patricia Keegan, Tara C. Mitchell, Rebecca A. Moss, Caroline Robert, Rajeshwari Sridhara, Janis M. Taube, Michael T. Tetzlaff, Jennifer A. Wargo, Keith T. Flaherty, Michael J. Kaplan, Suzanne L. Topalian, Ashley F. Ward, and Marc S. Hurlbert

## RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

- 402** **Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial**  
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Christian Baues, Ulrich Keller, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Michael Fuchs, Stephanie Sasse, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Carsten Kobe, and Paul J. Bröckelmann

## CLINICAL TRIALS: TARGETED THERAPY

- 408** **A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer**  
**A C** Yen-Shen Lu, Keun Seok Lee, Tsu-Yi Chao, Ling-Ming Tseng, Imjai Chitapanarux, Shin-Cheh Chen, Chien-Ting Liu, Joohyuk Sohn, Jee Hyun Kim, Yuan-Ching Chang, Youngsen Yang, Kanjana Shotelersuk, Kyung Hae Jung, Roberta Valenti, Cassandra Slader, Melissa Gao, and Yeon Hee Park  
See related commentary, p. 371

# TABLE OF CONTENTS

- 418 Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast Cancer**  
Sara M. Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa Nardi, Uz Stammberger, Ahmed M. Abdelhady, Shiling Ruan, and Soo Chin Lee  
See related commentary, p. 371

- 429 Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response**  
Fatima Karzai, Stephanie M. Walker, Scott Wilkinson, Ravi A. Madan, Joanna H. Shih, Maria J. Merino, Stephanie A. Harmon, David J. VanderWeele, Lisa M. Cordes, Nicole V. Carrabba, John R. Bright, Nicolas T. Terrigino, Guinevere Chun, Marijo Bilusic, Anna Couvillon, Amy Hankin, Monique N. Williams, Rosina T. Lis, Huihui Ye, Peter L. Choyke, James L. Gulley, Adam G. Sowalsky, Baris Turkbey, Peter A. Pinto, and William L. Dahut

- 438 Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma**

**A C** Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, Nicolas Isambert, Patricia Niccoli, Jaume Capdevila, Giuseppe Curigliano, Victor Moreno, Patricia Martin-Romano, Eric Baudin, Marina Arias, Sheila Mora, Juan de Alvaro, Jorge Di Martino, Josep L. Parra-Palau, Tania Sánchez-Pérez, Ida Aronchik, Ellen H. Filvaroff, Manisha Lamba, Zariana Nikolova, and Johann S. de Bono

- 447 Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers**  
Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, and David M. Hyman

## CLINICAL TRIALS: IMMUNOTHERAPY

- 460 OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors**  
**A C** Martin Gutierrez, Victor Moreno, Kimberley M. Heinhuis, Anthony J. Olszanski, Anna Spreafico, Michael Ong, Quincy Chu, Richard D. Carvajal, José Trigo, Maria Ochoa De Olza, Mariano Provencio, Filip Yves De Vos, Filippo De Braud, Stephen Leong, Deanne Lathers, Rui Wang, Palani Ravindran, Yan Feng, Praveen Aanur, and Ignacio Melero

- 473 CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma**  
Hui Liu, Wen Lei, Chaoting Zhang, Chunmei Yang, Juying Wei, Qunyi Guo, Xiaojun Guo, Zhilu Chen, Ying Lu, Ken H. Young, Zheming Lu, and Wenbin Qian

- 485 Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors**  
Osama E. Rahma, Joshua E. Reuss, Anita Giobbie-Hurder, Ghazaleh Shoja E Razavi, Osama Abu-Shawar, Pooja Mehra, Seema Gupta, Richard Simon, and Samir N. Khleif

## PRECISION MEDICINE AND IMAGING

- 492 Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy**  
Roberto Ferrara, Marie Naigeon, Edouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita, Matthieu Texier, Caroline Caramella, Lizza Hendriks, David Planchard, Jordi Remon, Sabina Sangaletti, Claudia Proto, Marina C. Garassino, Jean-Charles Soria, Aurelien Marabelle, Anne-Laure Voisin, Siham Farhane, Benjamin Besse, and Nathalie Chaput  
See related commentary, p. 374

- 504 Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial**  
Elena Guerini-Rocco, Kathryn P. Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Paola Rafaniello Raviele, Elisabetta Munzone, Roswitha Kammler, Patrick Neven, Erika Hitre, Guy Jerusalem, Edda Simoncini, Andrea Gombos, Ines Deleu, Per Karlsson, Stefan Aebi, Jacquie Chirgwin, Vincenzo Di Lauro, Alastair Thompson, Marie-Pascale Graas, Matthew Barber, Christel Fontaine, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Bettina Müller, Seamus O'Reilly, Angelo Di Leo, Aron Goldhirsch, Giuseppe Viale, Massimo Barberis, Meredith M. Regan, and Marco Colleoni

- 513 Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study**  
Alfredo Rivas-Delgado, Ferran Nadeu, Anna Enjuanes, Sebastián Casanueva-Eliceiry, Pablo Mozas, Laura Magnano, Natalia Castrejón de Anta, Jordina Rovira, Ivan Dlouhy, Silvia Martín, Miguel Osuna, Sonia Rodríguez, Marc Simó, Magda Pinyol, Tycho Baumann, Silvia Beà, Olga Balagué, Julio Delgado, Neus Villamor, Xavier Setoain, Elías Campo, Eva Giné, and Armando López-Guillermo

# TABLE OF CONTENTS

**522 Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers**

Erica S. Tsang, Cameron J. Grisdale, Erin Pleasance, James T. Topham, Karen Mungall, Caralyn Reisle, Caleb Choo, Marcus Carreira, Reanne Bowlby, Joanna M. Karasinska, Daniel MacMillan, Laura M. Williamson, Eric Chuah, Richard A. Moore, Andrew J. Mungall, Yongjun Zhao, Basile Tessier-Cloutier, Tony Ng, Sophie Sun, Howard J. Lim, David F. Schaeffer, Daniel J. Renouf, Stephen Yip, Janessa Laskin, Marco A. Marra, Steven J.M. Jones, and Jonathan M. Loree

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

**532 A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy**

Brian H. Santich, Sarah M. Cheal, Mahiuddin Ahmed, Michael R. McDevitt, Ouathek Ouerfelli, Guangbin Yang, Darren R. Veach, Edward K. Fung, Mitesh Patel, Daniela Burnes Vargas, Aiza A. Malik, Hong-Fen Guo, Pat B. Zanzonico, Sebastien Monette, Adam O. Michel, Charles M. Rudin, Steven M. Larson, and Nai K. Cheung

See related commentary, p. 377

**542 Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity**

Bangxing Hong, Valerie Chapa, Uksha Saini, Puneet Modgil, David E. Cohn, Guangan He, Zahid H. Siddik, Anil K. Sood, Yuanqing Yan, Karuppaiyah Selvendiran, Guangsheng Pei, Zhongming Zhao, Ji Young Yoo, and Balveen Kaur

**554 Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer**

Adam R. Wolfe, Ryan Robb, Ahmad Hegazi, Laith Abushahin, Linlin Yang, Duan-Liang Shyu, Jose G. Trevino, Zobeida Cruz-Monserrate, John R. Jacob, Kamalakannan Palanichamy, Arnab Chakravarti, and Terence M. Williams

**566 Characterizing CDK12-Mutated Prostate Cancers**

**A C**

Pasquale Rescigno, Bora Gurel, Rita Pereira, Mateus Crespo, Jan Rekowski, Mattia Rediti, Maiaalen Barrero, Joaquin Mateo, Diletta Bianchini, Carlo Messina, Maria D. Fenor de la Maza, Khobe Chandran, Juliet Carmichael, Christina Guo, Alec Paschalis, Adam Sharp, George Seed, Ines Figueiredo, Maryou Lambros, Susana Miranda, Ana Ferreira, Claudia Bertan, Ruth Riisnaes, Nuria Porta, Wei Yuan, Suzanne Carreira, and Johann S. de Bono

See related commentary, p. 380

**575 Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome**

Beata Wolska-Kusnierz, Agata Pastorczak, Wojciech Fendler, Anna Wakulinska, Bozena Dembowska-Baginska, Edyta Heropolitanska-Pliszka, Barbara Piątosza, Barbara Pietrucha, Krzysztof Kałwak, Marek Ussowicz, Anna Pieczonka, Katarzyna Drabko, Monika Lejman, Sylwia Koltan, Jolanta Gozdzik, Jan Styczynski, Alina Fedorova, Natalia Miakova, Elena Deripapa, Larysa Kostyuchenko, Zdenka Krenova, Eva Hlavackova, Andrew R. Gennery, Karl-Walter Sykora, Sujal Ghosh, Michael H. Albert, Dmitry Balashov, Mary Eapen, Peter Svec, Markus G. Seidel, Sara S. Kilic, Agnieszka Tomaszewska, Ewa Wiesik-Szewczyk, Alexandra Kreins, Johann Greil, Jochen Buechner, Bendik Lund, Hanna Gregorek, Krystyna Chrzanowska, and Wojciech Mlynarski

**585 Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers**

**A C**

Reema S. Wahdan-Alaswad, Susan M. Edgerton, Hiba Salem, Hyun Min Kim, Aik Choon Tan, Jessica Finlay-Schultz, Elizabeth A. Wellberg, Carol A. Sartorius, Britta M. Jacobsen, Bryan R. Haugen, Bolin Liu, and Ann D. Thor

**598 BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia**

Haley E. Ramsey, Dalton Greenwood, Susu Zhang, Merrida Childress, Maria P. Arrate, Agnieszka E. Gorska, Londa Fuller, Yue Zhao, Kristy Stengel, Melissa A. Fischer, Matthew C. Stubbs, Phillip C.C. Liu, Kelli Boyd, Jeffrey C. Rathmell, Scott W. Hiebert, and Michael R. Savona

**608 Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses**

David H. Aggen, Casey R. Ager, Aleksandar Z. Obradovic, Nivedita Chowdhury, Ali Ghasemzadeh, Wendy Mao, Matthew G. Chaimowitz, Zoila A. Lopez-Bujanda, Catherine S. Spina, Jessica E. Hawley, Matthew C. Dallos, Cheng Zhang, Vinson Wang, Hu Li, Xinzhen V. Guo, and Charles G. Drake

# TABLE OF CONTENTS

**622 Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia**

Yoon-Chi Han, Jennifer Kahler, Nicole Piché-Nicholas, Wenyue Hu, Stephane Thibault, Fan Jiang, Mauricio Leal, Madan Katragadda, Andreas Maderna, Russell Dushin, Nadira Prashad, Manoj B. Charati, Tracey Clark, L. Nathan Tumey, Xingzhi Tan, Andreas Giannakou, Edward Rosfjord, Hans-Peter Gerber, Lioudmila Tchistiakova, Frank Loganzo, Christopher J. O'Donnell, and Puja Sapro

**632 Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion**

Christian Watermann, Helen Pasternack, Christian Idel, Julika Ribbat-Idel, Johannes Brägelmann, Patrick Kuppler, Anne Offermann, Danny Jonigk, Mark Philipp Kühnel, Andreas Schröck, Eva Dreyer, Christian Rosero, Jacqueline Nathansen, Anna Dubrovskaya, Lars Tharun, Jutta Kirfel, Barbara Wollenberg, Sven Perner, and Rosemarie Krupar

**645 RNA sequencing and Immunohistochemistry Reveal *ZFN7* as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma**


Anna Esteve-Codina, Francesc Alameda, Cristina Carrato, Estela Pineda, Oriol Arpi, Maria Martinez-García, Mar Mallo, Marta Gut, Marc Dabad, Avelina Tortosa, Sonia Del Barco, Jaume Capellades, Josep Puig, Oscar Gallego, Teresa Pujol, Laura Oleaga, Miquel Gil-Gil, Cristian de Quintana-Schmidt, Izaskun Valduvico, Anna Martinez-Cardús, Beatriz Bellosillo, Ana Maria Muñoz-Marmol, Anna Esteve, Marta Domenech, Angels Camins, Jordi Craven-Bartle, Salvador Villa, Jordi Marruecos, Sira Domenech, Nuria de la Iglesia, and Carmen Balana

**AC** icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows a biopsy from a patient with metastatic non-small cell lung cancer with a cryptic *EML4-ALK* fusion. This fusion was not detected by ALK IHC and FISH due to the complex nature of the rearrangement; however, whole genome sequencing and RNA-seq identified the variant, and the patient had an excellent response to crizotinib. For details, see the article by Tsang and colleagues on page 522 of this issue.



# Clinical Cancer Research

**27 (2)**

*Clin Cancer Res* 2021;27:369-655.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/27/2>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/2>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.